Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.082
Neutral
RSI(14)
50.158
Neutral
STOCH(KDJ)(9,3,3)
26.364
Sell
ATR(14)
0.278
High Vlolatility
CCI(14)
-51.693
Neutral
Williams %R
68.639
Sell
TRIX(12,20)
0.576
Sell
StochRSI(14)
0.000
Oversold
Search
Abeona Therapeutics Inc
ABEOAdd to Watchlist
5.490USD
-0.110-1.96%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
312.90MMarket Cap
4.27P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Abeona Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Abeona Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 19.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Abeona Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Abeona Therapeutics Inc Highlights
StrengthsRisks
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 66.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.82M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 4.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.30M shares, decreasing 14.33% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 5.08K shares of this stock.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
19.500
Target Price
+248.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Abeona Therapeutics Inc is 7.23, ranking 115 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
9.10
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.63
Operational Efficiency
2.86
Growth Potential
10.00
Shareholder Returns
7.58
Abeona Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Abeona Therapeutics Inc is 7.23, ranking 86 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 4.27, which is 59.93% below the recent high of 6.84 and 426.13% above the recent low of -13.94.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 53/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Abeona Therapeutics Inc is 9.00, ranking 6 out of 155 in the Pharmaceuticals industry. The average price target is 19.00, with a high of 27.50 and a low of 14.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
19.500
Target Price
+248.21%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Abeona Therapeutics Inc
ABEO
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Abeona Therapeutics Inc is 6.85, ranking 73 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 5.96 and the support level at 5.12, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
5.668
Sell
MA10
5.780
Sell
MA20
5.607
Sell
MA50
5.123
Buy
MA100
5.149
Buy
MA200
5.373
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Abeona Therapeutics Inc is 7.00, ranking 51 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 70.85%, representing a quarter-over-quarter decrease of 10.33%. The largest institutional shareholder is James Simons, holding a total of 116.20K shares, representing 0.20% of shares outstanding, with 20.54% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Abeona Therapeutics Inc is 4.64, ranking 85 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.33
VaR
+6.86%
240-Day Maximum Drawdown
+42.32%
240-Day Volatility
+52.99%
Return
Best Daily Return
60 days
+9.58%
120 days
+9.58%
5 years
+25.28%
Worst Daily Return
60 days
-4.41%
120 days
-5.72%
5 years
-53.67%
Sharpe Ratio
60 days
+0.84
120 days
+1.40
5 years
-0.03
Risk Assessment
Maximum Drawdown
240 days
+42.32%
3 years
+63.48%
5 years
+93.33%
Return-to-Drawdown Ratio
240 days
-0.30
3 years
+0.14
5 years
-0.18
Skewness
240 days
+0.88
3 years
-1.85
5 years
-0.82
Volatility
Realised Volatility
240 days
+52.99%
5 years
+96.53%
Standardised True Range
240 days
+4.82%
5 years
+8.51%
Downside Risk-Adjusted Return
120 days
+300.86%
240 days
+300.86%
Maximum Daily Upside Volatility
60 days
+39.74%
Maximum Daily Downside Volatility
60 days
+34.74%
Liquidity
Average Turnover Rate
60 days
+2.45%
120 days
+2.40%
5 years
--
Turnover Deviation
20 days
+15.04%
60 days
+28.70%
120 days
+26.11%
Peer Comparison
Pharmaceuticals
Abeona Therapeutics Inc
ABEO
7.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
